Navigation Links
News briefs from the January issue of Chest
Date:1/5/2010

SMALL, THIN CHILDREN MAY HAVE POORER LUNG FUNCTION

A new study shows that poor lung function during adolescence and through midlife may be influenced by several factors, including birth weight, height, and gender. Researchers from Newcastle University in the United Kingdom analyzed health data from 252 patients, all aged 14 years. Follow-up data also were obtained for 122 of the patients at age 49 to 51. Results showed that several factors were related to poorer lung function (as measured by FEV1) at age 14, including lower height, lower BMI, being breast-fed for less than 4 weeks, and childhood respiratory disease. Furthermore, several factors predicted a decline in lung function between the ages of 49 to 51 years, including more cigarettes smoked in the lifetime, having a higher FEV1 at age 14, and being female. Researchers note that women reach their maximum FEV1 at a younger age than men, which may explain why, after age 14, the lung function of women declines at a higher rate than the lung function of men. This article is published in the January issue of Chest, the peer-reviewed journal of the American College of Chest Physicians.

TIOTROPIUM ASSOCIATED WITH REDUCED MORTALITY

New research suggests that tiotropium, a long-acting anticholinergic used in patients with COPD, may be associated with a reduction in all-cause mortality, cardiovascular mortality, and cardiovascular events. Researchers from Caritas-St. Elizabeth Medical Center in Boston, MA, reviewed the outcomes of 30 completed clinical trials in the tiotropium project database. Within the trials, 10,846 patients were treated with tiotropium and 8,699 patients received a placebo. Results indicated that patients treated with tiotropium had lower incidence rates (IR) of all-cause mortality, cardiovascular mortality, and cardiovascular events (IR = 3.44, .91, and 2.15 per 100 patients, respectively), compared with placebo (IR = 4.10, 1.24, and 2.67, respectively). Within the tiotropium group, the overall risk for serious or fatal lower respiratory events also was reduced. The mechanism by which tiotropium may reduce cardiovascular mortality is unclear, but researchers speculate that there may be an association with the reduction in respiratory events. The article is published in the January issue of Chest, the peer-reviewed journal of the American College of Chest Physicians.

IPRATROPIUM BROMIDE MAY INCREASE RISK FOR CARDIOVASCULAR EVENTS

Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Researchers from the University of Washington in Seattle, WA, and Hines VA Hospital in Hines, IL, conducted a cohort study on 82,717 US veterans with a new diagnosis of COPD between 1999 and 2002. Of the patients, 44 percent were exposed to anticholinergics (mainly ipratropium) at some time during the study. Patients were followed until they had their first hospitalization for a CVE, until they died, or until September 30, 2004. Within the cohort, 6,234 CVE were identified (44 percent heart failure, 28 percent acute coronary syndrome, and 28 percent dysrhythmias). Results showed that any exposure to anticholinergics within the past 6 months was associated with an increased risk of CVE. However, among patients who received anticholinergics more than 6 months prior, an elevated risk of CVE was not seen. Researchers note that their findings are consistent with previous concerns raised about the cardiovascular safety of ipratropium bromide. This study is published in the January issue of Chest, the peer-reviewed journal of the American College of Chest Physicians.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum
3. News briefs from the November issue of Chest
4. DuPont Group Vice President Briefs Investors on Performance Materials Segment
5. Nanotech Briefs Announces Call for Nominations for the Fourth Annual Nano 50(TM) Awards
6. News Briefs from Preventive Medicine 2008
7. Journal Chest -- March 2008 news briefs
8. News briefs: May issue of the journal Chest
9. Weill Cornell science briefs May 2008
10. News briefs from the American Society of Plastic Surgeons
11. News briefs from the American Society of Plastic Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: